Monte Rosa Therapeutics (GLUE) Gains from Sales and Divestitures (2023 - 2025)
Historic Gains from Sales and Divestitures for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $112159.0.
- Monte Rosa Therapeutics' Gains from Sales and Divestitures fell 809.2% to $112159.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $112159.0, marking a year-over-year decrease of 809.2%. This contributed to the annual value of $122034.0 for FY2024, which is 1981.15% up from last year.
- Per Monte Rosa Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $112159.0 for Q3 2025, which was down 809.2% from $112159.0 recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Gains from Sales and Divestitures registered a high of $122034.0 during Q3 2024, and its lowest value of $4691.0 during Q1 2024.
- Moreover, its 3-year median value for Gains from Sales and Divestitures was $99459.5 (2023), whereas its average is $85112.4.
- As far as peak fluctuations go, Monte Rosa Therapeutics' Gains from Sales and Divestitures plummeted by 8586.71% in 2024, and later surged by 3922.59% in 2025.
- Quarter analysis of 3 years shows Monte Rosa Therapeutics' Gains from Sales and Divestitures stood at $101855.0 in 2023, then grew by 19.81% to $122034.0 in 2024, then decreased by 8.09% to $112159.0 in 2025.
- Its Gains from Sales and Divestitures stands at $112159.0 for Q3 2025, versus $112159.0 for Q2 2025 and $122034.0 for Q4 2024.